Pfizer lands schizophrenia drug in $22M deal

Japan's Taisho has granted all commercial rights to its preclinical schizophrenia drug outside of Japan to Pfizer for $22 million up front. TS-032 is an mGluR agonist, which promises to influence the transmission of substances in the brain that is associated with schizophrenia. Taisho is an experienced player in the psychiatric drugs market. The Japanese company also stands to gain unspecified milestone payments for the drug.

- see this release
- read the AP report

Suggested Articles

Almirall and Iktos will use the latter's AI technology to design new compounds that tick multiple drug criteria boxes.

Pfizer’s 2017 spinout company SpringWorks has lost president and founder Lara Sullivan, M.D., who has moved over to Pyxis Oncology as its new chief.

In this week's EuroBiotech Report, Sanofi inks $2.5B Synthorx takeover and posts sutimlimab data, Roche shares bispecific results and more.